Usage of Nivolumab – Platinum Containing STAT1 Molecule for Suppression PD-1/PD-L1 Genes in PD-1/PD-L1 Expressing Cancer Cells

1
Waleed O. Atta
Waleed O. Atta
1 Assiut University

Send Message

To: Author

GJMR Volume 22 Issue B2

Article Fingerprint

ReserarchID

PDDTMYT7S0

Usage of Nivolumab – Platinum Containing STAT1 Molecule for Suppression PD-1/PD-L1 Genes in PD-1/PD-L1 Expressing Cancer Cells Banner
  • English
  • Afrikaans
  • Albanian
  • Amharic
  • Arabic
  • Armenian
  • Azerbaijani
  • Basque
  • Belarusian
  • Bengali
  • Bosnian
  • Bulgarian
  • Catalan
  • Cebuano
  • Chichewa
  • Chinese (Simplified)
  • Chinese (Traditional)
  • Corsican
  • Croatian
  • Czech
  • Danish
  • Dutch
  • Esperanto
  • Estonian
  • Filipino
  • Finnish
  • French
  • Frisian
  • Galician
  • Georgian
  • German
  • Greek
  • Gujarati
  • Haitian Creole
  • Hausa
  • Hawaiian
  • Hebrew
  • Hindi
  • Hmong
  • Hungarian
  • Icelandic
  • Igbo
  • Indonesian
  • Irish
  • Italian
  • Japanese
  • Javanese
  • Kannada
  • Kazakh
  • Khmer
  • Korean
  • Kurdish (Kurmanji)
  • Kyrgyz
  • Lao
  • Latin
  • Latvian
  • Lithuanian
  • Luxembourgish
  • Macedonian
  • Malagasy
  • Malay
  • Malayalam
  • Maltese
  • Maori
  • Marathi
  • Mongolian
  • Myanmar (Burmese)
  • Nepali
  • Norwegian
  • Pashto
  • Persian
  • Polish
  • Portuguese
  • Punjabi
  • Romanian
  • Russian
  • Samoan
  • Scots Gaelic
  • Serbian
  • Sesotho
  • Shona
  • Sindhi
  • Sinhala
  • Slovak
  • Slovenian
  • Somali
  • Spanish
  • Sundanese
  • Swahili
  • Swedish
  • Tajik
  • Tamil
  • Telugu
  • Thai
  • Turkish
  • Ukrainian
  • Urdu
  • Uzbek
  • Vietnamese
  • Welsh
  • Xhosa
  • Yiddish
  • Yoruba
  • Zulu

Blockage of PD-1 proteins by immune checkpoint inhibitors showed an accepted therapeutic effect in cancer. But; tumor microenvironment exerts its antitumor influence by various mechanisms. Malignant cells have the ability of PD-1/PD-L1 protein over synthesis, which can be a defense action against immune checkpoint inhibitors and immunotherapy. Binding nivolumab with platinum-containing STAT1 will be used to reduce PD-1 genetic level. Nivolumab has the option of endocytosis, while STAT1 is the transcription factor that binds to the DNA, specifically PD-1 gene. STAT1 is the activated protein in response to multiple cytokines stimulation of cancer cells, which are the same for increasing PD-1/ PD-L1 upregulation. The used STAT1 in our therapeutic strategy is the activated form and loaded with platinum particles for damaging DNA bases in PD-1 promoter regions upon translocation to the nucleus. STAT1platinum molecule is connected to nivolumab Fc region by solamargine polymer for selective cancer cell targeting.

Funding

No external funding was declared for this work.

Conflict of Interest

The authors declare no conflict of interest.

Ethical Approval

No ethics committee approval was required for this article type.

Data Availability

Not applicable for this article.

Waleed O. Atta. 2026. \u201cUsage of Nivolumab – Platinum Containing STAT1 Molecule for Suppression PD-1/PD-L1 Genes in PD-1/PD-L1 Expressing Cancer Cells\u201d. Global Journal of Medical Research - B: Pharma, Drug Discovery, Toxicology & Medicine GJMR-B Volume 22 (GJMR Volume 22 Issue B2): .

Download Citation

Nivolumab platinum combining STAT1 molecule study for cancer suppression and immunotherapy research.
Journal Specifications

Crossref Journal DOI 10.17406/gjmra

Print ISSN 0975-5888

e-ISSN 2249-4618

Keywords
Classification
GJMR-B Classification: DDC Code: 784.2 LCC Code: M3.1
Version of record

v1.2

Issue date

July 9, 2022

Language

English

Experiance in AR

The methods for personal identification and authentication are no exception.

Read in 3D

The methods for personal identification and authentication are no exception.

Article Matrices
Total Views: 1591
Total Downloads: 16
2026 Trends
Research Identity (RIN)
Related Research

Published Article

Blockage of PD-1 proteins by immune checkpoint inhibitors showed an accepted therapeutic effect in cancer. But; tumor microenvironment exerts its antitumor influence by various mechanisms. Malignant cells have the ability of PD-1/PD-L1 protein over synthesis, which can be a defense action against immune checkpoint inhibitors and immunotherapy. Binding nivolumab with platinum-containing STAT1 will be used to reduce PD-1 genetic level. Nivolumab has the option of endocytosis, while STAT1 is the transcription factor that binds to the DNA, specifically PD-1 gene. STAT1 is the activated protein in response to multiple cytokines stimulation of cancer cells, which are the same for increasing PD-1/ PD-L1 upregulation. The used STAT1 in our therapeutic strategy is the activated form and loaded with platinum particles for damaging DNA bases in PD-1 promoter regions upon translocation to the nucleus. STAT1platinum molecule is connected to nivolumab Fc region by solamargine polymer for selective cancer cell targeting.

Our website is actively being updated, and changes may occur frequently. Please clear your browser cache if needed. For feedback or error reporting, please email [email protected]
×

This Page is Under Development

We are currently updating this article page for a better experience.

Request Access

Please fill out the form below to request access to this research paper. Your request will be reviewed by the editorial or author team.
X

Quote and Order Details

Contact Person

Invoice Address

Notes or Comments

This is the heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

High-quality academic research articles on global topics and journals.

Usage of Nivolumab – Platinum Containing STAT1 Molecule for Suppression PD-1/PD-L1 Genes in PD-1/PD-L1 Expressing Cancer Cells

Waleed O. Atta
Waleed O. Atta Assiut University

Research Journals